SMART therapy linked to better asthma outcomes

Single maintenance and reliever therapy (SMART) is associated with a significantly lower risk of asthma exacerbations than conventional separate maintenance and reliever therapy, according to a new meta-analysis.

Evidence suggests that SMART improves clinical outcomes in adults with asthma. | iStock
Evidence suggests that SMART improves clinical outcomes in adults with asthma. | iStock

US researchers identified sixteen randomised trials, involving 22,748 patients, from numerous databases including MEDLINE, EMBASE, the Cochrane register and the Cochrane Database of Systematic Reviews published up to November 2017.

The trials compared the use of SMART with the conventional approach of using inhaled corticosteroids ([ICS] with or without a long-acting β-agonist [LABA]) as the maintenance therapy and short-acting β-agonists as the reliever therapy, among patients 5 years or older with persistent asthma. 

Further information

JAMA meta-analysis

Among patients 12 years or older (n = 22,524), the results showed that SMART was associated with a reduced risk of asthma exacerbations compared with ICS/LABA maintenance therapy when the latter was given at either the same dose (risk ratio [RR] 0.68 [95% CI 0.58–0.80]; risk difference [RD], −6.4% [95% CI −10.2% to −2.6%]) or a higher dose (RR, 0.77 [95% CI 0.60–0.98]; RD, −2.8% [95% CI −5.2% to −0.3%]).

Similar results were seen when SMART was compared with ICS alone as the maintenance therapy.

Increased compliance

The findings are consistent with BTS/SIGN guidance on the management of asthma, which advocates the use of SMART therapy in patients whose asthma remains poorly controlled despite the regular use of an ICS. Prescribing of a combination inhaler containing both a steroid and a LABA is recommended in order to aid treatment compliance and ensure that the LABA is not taken without the steroid.

There are currently three formoterol/budesonide combination inhalers licensed for SMART in the UK: Symbicort Turbohaler (100/6 and 200/6), DuoResp Spiromax (160/4.5) and Fobumix Easyhaler (160/4.5 and 80/4.5) and one formoterol/beclometasone inhaler: Fostair (100/6).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more